



May 2011

# Disclaimer



This Document comprises an institutional presentation (the "Presentation") which has been prepared by and is the sole responsibility of ValiRx plc (the "Company"). The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever or constitute an invitation or inducement to engage in investment activity under section 21 of the UK Financial Services and Markets Act 2000.

Notwithstanding the above, in the United Kingdom, this Presentation is only being given to persons reasonably believed by the Company to be investment professionals within the meaning of paragraph (5) of Article 19 or to high net worth companies or unincorporated associations within the meaning of paragraph (2) of Article 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529). This Presentation is only being sent to persons reasonably believed by the Company to be investment professionals or to persons to whom it may otherwise be lawful to distribute it. If you are not such a person (i) you should not have received this Presentation and (ii) please return this Presentation to the Company's registered office as soon as possible and take no other action. By accepting this Presentation the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive this Presentation.

This Presentation is not intended to be distributed, or passed on, directly or indirectly, to any other class of person and in any event under no circumstances should persons of any other description rely or act upon the contents of this Presentation. This Presentation and its contents are confidential and must not be distributed or passed on, directly or indirectly, to any other person. This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person.

No representation or warranty, express or implied, is made or given by or on behalf of the Company, its advisers or any of their respective parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of the directors, officers or employees of any such person as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. No person has been authorised to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. The contents of this Presentation are not to be construed as legal, financial or tax advice.

The information has not been verified nor independently verified by the Company's advisers and is subject to material updating, revision and further amendment. The Company has not been, and will not be, registered under the United States Investment Company Act of 1940, as amended, and investors will not be entitled to the benefits of that Act. Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America or its territories or possessions (the "United States"), or distributed, directly or indirectly, in the United States, or to any U.S Person as defined in Regulation S under the Securities Act 1933 as amended, including U.S resident corporations or other entities organised under the laws of the United States or any state thereof or non-U.S branches or agencies of such corporations or entities or into Canada, Australia, Japan, South Africa or the Republic of Ireland. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in Canada, Australia, Japan, South Africa or the Republic of Ireland, or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of United States or other national securities law.

**Forward-Looking Statements.** Information contained in this Presentation may include 'forward-looking statements'. All statements other than statements of historical facts included herein, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's business) are forward-looking statements. Such forward-looking statements are based on a number of assumptions regarding the Company's present and future business strategies and the environment in which the Company expects to operate in future. Actual results may vary materially from the results anticipated by these forward-looking statements as a result of a variety of factors. These forward-looking statements speak only as to the date of this Presentation and cannot be relied upon as a guide to future performance. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this Presentation to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

# Overview



- Biopharmaceutical company specialising in oncology therapeutics and diagnostics
  - Listed on AIM 2006
- Portfolio of innovative technologies and products with worldwide exclusive rights and granted patents
- Two complementary sections with strong development pipelines
  - Marketing and Distribution- online distribution [www.valimedix.com](http://www.valimedix.com)
    - Revenues from Self-Check diagnostic products
  - Therapeutics and companion diagnostics
    - Late pre-clinical leading to clinical trials
- Balanced risk, reward through diagnostics and therapeutics
  - Develop diagnostics through distribution, marketing authorisation and partner
  - Develop therapeutics through proof of concept in man and then license and/or partner
- Partners
  - Cancer Research UK – licence for Val 201
  - Imperial College – development of Val 101
  - Eurostars konsortium development of Val 101
  - Oxford University – development of Val 201 in two indications

# Our vision



- Exploit expertise in epigenomics with major focus on oncology
- ValiRx approach to personalised medicine



**Early stage detection of disease**  
*diagnostics*

**Specific diagnosis and therapeutic strategy**  
*diagnostics + therapeutic understanding*

**Therapeutic applications**  
*therapeutics*

**Therapeutic outcome and success**  
*diagnostics*

**Potential supporting therapy**  
*therapeutics*

1. GeneICE™ gene-silencing and discovery platform
2. VAL 101
  - Pre clinical studies to date show effectiveness in prostate, ovarian and pancreatic cancer cells
  - Well positioned as drug target discovery and validation tool in oncology and neurological diseases
3. VAL 201
  - Preclinical studies indicate potential in halting prostate cancer tumour growth with good preclinical data
  - Potential additional indications
4. HyperGenomics™
  - High throughput biomarker and diagnostic platform – epigenomic profiling test in development
5. HPV
  - High / medium/ low risk indication for cervical cancer
6. Self-check
  - A range of consumer oriented healthcare and wellbeing diagnostic products in the market

- 9 products in the market
- All CE marked – regulatory approval
- Active managing of personalised health
- Consumer awareness and education
- Marketing and sales activities

PSA  
Bowel test  
Chlamydia

# SELF Check Diagnostic Test Kits

For more information consult your pharmacist



**Cholesterol Level Test**  
Sterile rapid test for determining whether your personal total cholesterol level is within normal limits. Requires only one drop of whole blood. Fast and reliable - visible result within 3 minutes.



**Prostate Health Test**  
Sterile rapid blood test to detect whether your prostate specific antigen (PSA) is above normal levels. Fast and reliable - visible result within 10 minutes.



**Urine Infection Test**  
Sterile rapid test to detect indirect signs of urine infection. Fast and reliable - visible result within 2 minutes. Detects protein, nitrite and leucocytes, not normally present in urine.



**Blood Glucose level Test**  
Sterile rapid test to determine whether blood glucose levels are within normal limits. Requires only one drop of whole blood. Fast and reliable - visible result within 2 minutes. Detects levels of blood glucose ranging between 1.55mmol/l - 1000mg/dl



**Female Chlamydia Test**  
Sterile rapid swap test to detect the presence of Chlamydia trachomatis. Easy to use - 2 easy steps. Unique "wand" design. Visible result within 10 minutes.



**Bowel Health Test**  
Sterile rapid test to detect the first symptoms of colon polyps, adenomas, carcinomas and other silent lesions. Detects occult (hidden) bleeding: 0.14ul blood/1g stool (highly specific for human haemoglobin). Fast and reliable - visible result within 5 minutes. This test has been evaluated by the largest European screening study (150,000 people over a 5 year period)



**Menopause Test**  
Sterile rapid urine test to detect human follicle stimulating hormone (a marker for transition into post-menopause). Fast and reliable - visible result within 10 minutes. Sensitive to 25mIU hFSH/ml.




**Multi Drug Test**  
Sterile rapid one step urine test for the qualitative detection of the commonly abused drugs: Cocaine (CO), Amphetamine (AMP), Cannabis (THC), Methamphetamine (MAMP), Codeine (CO), Heroin (H), Benzodiazepines (BDZ). Fast and reliable result within 5 minutes. Contains 1 single test.



**Stomach Ulcer Test**  
Sterile rapid test to detect an infection of Helicobacter pylori, which is linked to stomach ulcers. Fast and reliable - visible result within 10 minutes.



# Epigenomics: Revolutionary approach to disease identification and treatment





# Epigenomics platform




- Global market for epigenomic products to be worth \$6billion by 2014\*
- Emerging field in the early part of its lifecycle\*
- Epigenomic drugs will account for the majority of future sales in the industry\*
- The largest segment of the market, pharmaceuticals, is projected to increase at 46% per annum\*
- Second largest segment is research tools\*
- Valirx technologies are well placed within the epigenomic field
- Solid research behind – World wide exclusive licences from Imperial College and CRT

# GeneICE™ platform – Rebellious genes


- GeneICE™: Gene Inactivation by Chromatin Engineering
  - Patents granted in Europe, US and Australia
- Therapeutics and discovery platform
  - GeneICE™ recruits and applies gene silencing complexes known as Histone Deacetylase Complexes (HDACs) to target genes

## A cellular mechanism for long term gene repression



- Unmet clinical need in the cancer sector
- 40 drug discovery collaborations between big pharma and biotech companies in the last 18 months
- Demand by big pharma and biotech to fill new product pipeline
- Licensing deals, M&A activities, sell of companies
- Deals from research to late stage clinical phase.
- Valirx have therapeutic development programmes in oncology and a licensed platform technology with a potential pipeline for several compounds

- Val 201 peptide has shown in vivo activity
- Hormone refractory and metastatic tumours



**Key**  
Vehicle- Negative Control  
Ss- Negative Control  
S1- Treatment Val 201

**Virtually complete repression of tumour growth in Xenograft model**

- Preclinical and early stage clinical development, licensing and/or partnering deal
- Each compound/programme can be licensed separately
- Examples of 2011 deal structures:
  - **Discovery**  
\$6m upfront payment, up to \$200m for development
  - **Preclinical development**  
\$8m upfront \$200m milestone payments, royalties on sales  
\$20m upfront, potential milestone payments up to \$630
  - **Phase I development**  
\$50m upfront payment up to \$450m in milestones, double digit royalties
  - **Phase II and beyond**

# Valirx position



- Innovative technologies and products
- Solid scientific research
- Funding for development
- Collaborations with first class institutions
- Resources for a solid data development for any licensing/partnering discussions
- Several development programmes and revenue generation
- Product innovation partners

## Achieved 2010

- Progress in several areas of business
  - Successful completion of additional preclinical work with GeneICE therapeutics with accelerated development – Eurostar
  - Expansion of Self – Check kit range (OTC)
  - Revenue generation
  - VAL 201 further proof of concept
  - Review of business model
  - Restructuring of finances and reduction of cost base



## Targets 2011

- Accelerate pre clinical progress of Val101 and Val201
- Support sales and marketing activities of Valimedix
- Develop companion diagnostics for use in therapeutic programmes
- Support development of HPV diagnostic testing

# Thank You

Dr Satu Vainikka  
[satu.vainikka@valirx.com](mailto:satu.vainikka@valirx.com)